HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

N-(2-cyanoethylene)urea (BA 1)

structure
Also Known As:
BA 1; BA-1; 2-cyano-1-aziridinecarboxamide
Networked: 41 relevant articles (4 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Martuzzi, Roberto: 1 article (11/2015)
2. Dieguez, Sebastian: 1 article (11/2015)
3. Blanke, Olaf: 1 article (11/2015)
4. Gruetter, Rolf: 1 article (11/2015)
5. Serino, Andrea: 1 article (11/2015)
6. van der Zwaag, Wietske: 1 article (11/2015)
7. Jiang, Bing: 1 article (01/2014)
8. Liu, Tian-Qiang: 1 article (01/2014)
9. Yu, Xiao-Bo: 1 article (01/2014)
10. Wang, Gao-Xue: 1 article (01/2014)

Related Diseases

1. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
05/01/1982 - "Monoclonal antibody BA-1 binds to B lymphocytes, to cells from most cases of non-T acute lymphoblastic leukemia (ALL), and weakly to neutrophils. "
01/01/1986 - "These results suggest that consideration be given to incorporation of BA-1, 2, 3 + complement and mafosfamid combination treatment in autologous bone marrow transplantation for acute lymphoblastic leukemia."
09/01/1985 - "Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement."
02/15/1992 - "Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging."
11/01/1981 - "In addition, each major group had multiple phenotypes when analyzed with seven immunological markers including the erythrocyte rosette receptor, surface immunoglobulin, cytoplasmic immunoglobulin M, the early lymphocyte-acute lymphoblastic leukemia antigen, monoclonal antibody TA-1, monoclonal antibody BA-1, and a monoclonal antibody against HLA-DR. While immunological heterogeneity was demonstrable within each group, distinct biological behavior was observed, with T-ALL and B-ALL generally presenting as "lymphomas" and the others presenting as "leukemias." Morphological analysis using the French-American-British classification provided independent information in the definition of groups with differing clinical behavior. "
2. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
11/01/1984 - "These findings indicate that: (a) practically all cases of cALL appear to be of B cell origin as shown by gene rearrangement analysis; (b) DNA studies are relevant for a more precise characterization of individual cases of undifferentiated acute leukemia; (c) a complete survey for B cell markers may establish the B cell origin of the cALL blasts, as long as the analysis on primary cells is complemented by differentiation induction assessment; and (d) most cases of non-T ALL appear to be characterized by the expansion of neoplastic cells "frozen" at different levels along the B cell differentiation pathway, the first detectable marker being heavy chain gene rearrangement, followed by BA-1, B1, and CyIg expression."
01/01/1985 - "Cells from all cases were characterized with a panel of 15 monoclonal antibodies: 3A1 was constantly positive; J5, BA-1, OKT6, Leu-7, and other monoclonal antibodies reactive with T-cells (OKT3, OKT4, OKT8, OKT11, Leu-1, T65) were negative; only two cases had weak positivity with OKT11 and Leu-1, respectively; cells from all cases were surface immunoglobulin (SIg)-negative; three out of the five cases were OKT10-positive and three OKT9-positive; none of the cases reacted with OKM1 and anti-HLA-DR. Our findings indicate that the use of 3A1 monoclonal antibody was helpful in the recognition of individual cases of T-ALL otherwise considered as unclassified-ALL (U-ALL). "
11/01/1981 - "In addition, each major group had multiple phenotypes when analyzed with seven immunological markers including the erythrocyte rosette receptor, surface immunoglobulin, cytoplasmic immunoglobulin M, the early lymphocyte-acute lymphoblastic leukemia antigen, monoclonal antibody TA-1, monoclonal antibody BA-1, and a monoclonal antibody against HLA-DR. While immunological heterogeneity was demonstrable within each group, distinct biological behavior was observed, with T-ALL and B-ALL generally presenting as "lymphomas" and the others presenting as "leukemias." Morphological analysis using the French-American-British classification provided independent information in the definition of groups with differing clinical behavior. "
3. Prolapse
4. Leukemia
06/01/1985 - "Consonant with prior serologic studies with the use of BA-1, we could identify gp45/55/65 on B lymphocytes, B cell precursor acute lymphoblastic leukemias, neutrophils, and eosinophils. "
10/01/1986 - "Competitive binding experiments show that binding of SN3 to the leukemia cells was blocked almost completely by SN3a and SN3b, as well as by BA-1. "
11/01/1984 - "These findings indicate that: (a) practically all cases of cALL appear to be of B cell origin as shown by gene rearrangement analysis; (b) DNA studies are relevant for a more precise characterization of individual cases of undifferentiated acute leukemia; (c) a complete survey for B cell markers may establish the B cell origin of the cALL blasts, as long as the analysis on primary cells is complemented by differentiation induction assessment; and (d) most cases of non-T ALL appear to be characterized by the expansion of neoplastic cells "frozen" at different levels along the B cell differentiation pathway, the first detectable marker being heavy chain gene rearrangement, followed by BA-1, B1, and CyIg expression."
01/01/1982 - "BA-1, BA-2 and BA-3 are useful tools for analysing the developmental options of normal lymphoid cells and for "cleaning up" leukemia/lymphoma cells in selected cases of autologous bone marrow transplantation."
08/01/1988 - "With the use of quantitative flow cytometric techniques to assess heterogeneity of antigen expression, the findings indicate that phenotypic heterogeneity within neoplasms from individual patients exists for a number of B-cell-related monoclonal antibodies, including B1, common acute lymphocyte leukemia antigen (CALLA), Ia, Ba-1, DLC-48, and LN-1. "
5. Infection

Related Drugs and Biologics

1. Monoclonal Antibodies
2. N-methyl-valyl-amiclenomycin (BA 2)
3. Complement System Proteins (Complement)
4. Immunoglobulins (Immunoglobulin)
5. HLA-DR Antigens (HLA-DR)
6. Muromonab-CD3 (Muromonab CD3)
7. perfosfamide
8. DNA (Deoxyribonucleic Acid)
9. Antigens
10. Immunoglobulin M (IgM)

Related Therapies and Procedures

1. Bone Marrow Transplantation (Transplantation, Bone Marrow)
2. Bone Marrow Purging
3. Microspheres (Microsphere)
4. Oral Administration